Inspira Technologies

Inspira TechnologiesInspira Technologies
Inspira Technologies

Inspira Technologies

Medical technology company developing a less-invasive respiratory support system.

Website
DR 362018Active60Tel Aviv, Israel
Rate
Advertise here

About

Inspira Technologies develops advanced respiratory care solutions, including the INSPIRA™ ART500, a novel technology designed to elevate oxygen saturation levels without mechanical ventilation. Their products aim to provide an alternative to invasive procedures for patients experiencing acute respiratory distress, potentially revolutionizing the mechanical ventilation market. The company also offers the INSPIRA™ ART100 for cardiopulmonary bypass procedures and the HYLA™ blood sensor for continuous monitoring.
Frequently asked

What does Inspira Technologies do?

Inspira Technologies develops advanced respiratory care solutions, including the INSPIRA™ ART500, a novel technology designed to elevate oxygen saturation levels without mechanical ventilation. Their products aim to provide an alternative to invasive procedures for patients experiencing acute respiratory distress, potentially revolutionizing the mechanical ventilation market. The company also offers the INSPIRA™ ART100 for cardiopulmonary bypass procedures and the HYLA™ blood sensor for continuo…

What is Inspira Technologies's revenue?

StartupHub estimates Inspira Technologies's annual revenue at $20.6M (range $11.2M to $35.5M, 68% confidence), based on comparable companies in the sector.

Where is Inspira Technologies headquartered?

Inspira Technologies is headquartered in Tel Aviv, Israel.

When was Inspira Technologies founded?

Inspira Technologies was founded in 2018.

What industry does Inspira Technologies operate in?

Inspira Technologies operates in Healthcare, Medical Device, Respiratory, MedTech, HealthTech, Respiratory Care.

How many employees does Inspira Technologies have?

Inspira Technologies has approximately 60 people on record.

HEADCOUNT
60
DOMAIN RATING
36
Comments

No comments yet. Be the first to share your take.